Choline-phosphate cytidylyltransferase-α as a possible predictor of survival and response to cisplatin neoadjuvant chemotherapy in urothelial cancer of the bladder

Figures & data

Figure 1. Flowchart showing inclusion of patients from the Nordic randomized combined trials.

Figure 2. Sample of immunohistochemical images of (a) choline-phosphate cytidylyltransferase-α (CCT-α)-negative and (b) CCT-α-positive expression (20× magnification).

Table 1. Clinicopathological characteristics of all 238 eligible patients.

	Discovery (n = 61)		Validation (n = 177)
	CCT-α negative	CCT-α positive	CCT-α negative	CCT-α positive
Total	46 (100)	15 (100)	134 (100)	43 (100)
T2	16 (35)	3 (20)	57 (43)	25 (58)
T3–4	30 (65)	12 (80)	77 (57)	18 (42)
Male	38 (83)	13 (87)	109 (81)	35 (81)
Female	8 (17)	2 (13)	25 (19)	8 (19)
NAC	24 (52)	5 (13)	66 (49)	25 (58)
no-NAC	22 (48)	10 (67)	68 (51)	18 (42)
Age (years)	62 ± 7	60 ± 8	64 ± 9	64 ± 7

Data are shown as n (%) or mean ± SD.

No significant differences were detected between choline-phosphate cytidylyltransferase-α (CCT-α)-negative and CCT-α-positive groups.

Figure 3. Overall survival in months from randomization in (a) choline-phosphate cytidylyltransferase-α (CCT-α)-negative patients (n = 46) and (b) CCT-α-positive patients (n = 15) enrolled in the discovery data set.

Figure 4. Overall survival in months from randomization in (a) choline-phosphate cytidylyltransferase-α (CCT-α)-negative patients (n = 132) and (b) CCT-α-positive patients (n = 43) enrolled in the validation data set.

Table 2. Multivariate analysis of overall survival in the pooled data set of all 238 patients.

	p	HR	95% CI for HR
Gender (female/male)	0.24	1.32	0.83–2.12
Age	0.19	1.01	0-99–1.04
T3–4/T2	0.09	1.4	0.94–2.06
no-NAC/NAC	0.001	1.87	1.27–2.75
Nordic Study II/I	0.27	1.29	0.82–2.02
CCT-α negative/positive	0.018	1.80	1.11–2.93

HR: hazard ratio; CI: confidence interval; no-NAC: cystectomy only; NAC: neoadjuvant cisplatin chemotherapy plus cystectomy; CCT-α: choline-phosphate cytidylyltransferase-α.